Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven stage IC, II, III, or IV ovarian epithelial carcinoma or
primary peritoneal serous carcinoma

- Prior complete response to 1 platinum-based chemotherapy regimen consisting of at
least 5 courses

- Absence of disease on physical and radiological exam (CT scan/MRI)

- CA 125 normal

- No visible evidence of malignant disease on second-look laparoscopy

- No disease relapse even if complete response to a second course of chemotherapy

- Prior bilateral oophorectomy with or without salpingectomy, omentectomy, and total or
partial abdominal hysterectomy required

- No known metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-2

Life expectancy:

- At least 3 months

Hematopoietic:

- WBC at least 3,000/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 10.0 g/dL

Hepatic:

- SGOT/SGPT no greater than 2 times upper limit of normal

Renal:

- Creatinine no greater than 2.0 mg/dL

Other:

- No other malignancy except basal cell skin cancer

- No serious physical or psychiatric disease that would preclude study entry

- No significant loculation that would preclude good distribution of study medication

- Human antimouse antibody negative

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- No prior murine antibody

Chemotherapy:

- See Disease Characteristics

- No more than 4-8 weeks since prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- Not specified

Surgery:

- See Disease Characteristics

Other:

- No concurrent participation in other trials involving adjuvant cancer treatment

- No other concurrent experimental therapies